These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 26684470)

  • 1. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
    Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
    BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of the intrinsic molecular subtypes of breast cancer.
    Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
    Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
    Ring BZ; Hout DR; Morris SW; Lawrence K; Schweitzer BL; Bailey DB; Lehmann BD; Pietenpol JA; Seitz RS
    BMC Cancer; 2016 Feb; 16():143. PubMed ID: 26908167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
    Masuda H; Baggerly KA; Wang Y; Zhang Y; Gonzalez-Angulo AM; Meric-Bernstam F; Valero V; Lehmann BD; Pietenpol JA; Hortobagyi GN; Symmans WF; Ueno NT
    Clin Cancer Res; 2013 Oct; 19(19):5533-40. PubMed ID: 23948975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
    Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
    Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
    Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
    Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
    Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
    J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.
    Echavarria I; López-Tarruella S; Picornell A; García-Saenz JÁ; Jerez Y; Hoadley K; Gómez HL; Moreno F; Monte-Millan MD; Márquez-Rodas I; Alvarez E; Ramos-Medina R; Gayarre J; Massarrah T; Ocaña I; Cebollero M; Fuentes H; Barnadas A; Ballesteros AI; Bohn U; Perou CM; Martin M
    Clin Cancer Res; 2018 Apr; 24(8):1845-1852. PubMed ID: 29378733
    [No Abstract]   [Full Text] [Related]  

  • 18. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
    Bonnefoi H; Litière S; Piccart M; MacGrogan G; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Moldovan C; Bodmer A; Zaman K; Cufer T; Campone M; Luporsi E; Malmström P; Werutsky G; Bogaerts J; Bergh J; Cameron DA;
    Ann Oncol; 2014 Jun; 25(6):1128-36. PubMed ID: 24618153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
    Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
    Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.